GRAIL Inc (GRAL)
NASDAQ:GRAL
Want to see GRAL full AI Analyst Report?
GRAL Stock Chart & Stats
$51.71
-$1.19(-6.66%)
At close: 4:00 PM EST
$51.71
-$1.19(-6.66%)
Day’s Range― - ―
52-Week Range$29.95 - $118.84
Previous CloseN/A
Volume371.20K
Average Volume (3M)892.89K
Market Cap
$2.57B
Enterprise Value$2.56B
Total Cash (Recent Filing)$904.43M
Total Debt (Recent Filing)$98.01M
Price to Earnings (P/E)―
Beta2.43
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,020,256
10 Day Avg. Volume926,117
30 Day Avg. Volume892,889
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.22
Price to Sales (P/S)21.37
P/FCF Ratio-10.52
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue17.41
Enterprise Value/Gross Profit-40.96
Enterprise Value/Ebitda-6.90
Forecast
1Y Price Target
$66.86Price Target Upside29.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceManagement highlighted a substantial reduction in late-stage cancer detections in the test arm and a marked increase in early-stage findings, supporting the test's potential clinical value and persuasiveness to payers and clinicians.
Commercial MomentumManagement maintained revenue growth guidance for Galleri and plans to expand the U.S. commercial sales force, indicating sustained commercial traction and potential upside to testing volume.
Leadership And Regulatory ExpertiseAnalyst notes that the appointment of Josh Ofman preserves leadership continuity and brings deep experience in regulatory and reimbursement strategy that could accelerate clinical, regulatory, and commercial progress.
Bears Say
Funding UncertaintyA planned external investment from Samsung remains incomplete due to challenges at a government agency, leaving anticipated funding uncertain and pressuring liquidity planning.
Trial Outcome And Reimbursement UncertaintyNHS-Galleri did not meet its primary endpoint, creating uncertainty about how payers will interpret the evidence and complicating the path to broad reimbursement such as Medicare coverage.
Valuation And Cash Flow RiskThe stock has run up to a premium relative to diagnostic peers while cash burn remains a concern despite reductions, limiting near-term upside and increasing execution risk.
GRAIL Inc News
GRAL FAQ
What was GRAIL Inc’s price range in the past 12 months?
GRAIL Inc lowest stock price was $29.95 and its highest was $118.84 in the past 12 months.
What is GRAIL Inc’s market cap?
GRAIL Inc’s market cap is $2.57B.
When is GRAIL Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were GRAIL Inc’s earnings last quarter?
Currently, no data Available
Is GRAIL Inc overvalued?
According to Wall Street analysts GRAIL Inc’s price is currently Undervalued.
Does GRAIL Inc pay dividends?
GRAIL Inc does not currently pay dividends.
What is GRAIL Inc’s EPS estimate?
GRAIL Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GRAIL Inc have?
GRAIL Inc has 41,020,256 shares outstanding.
What happened to GRAIL Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of GRAIL Inc?
Currently, no hedge funds are holding shares in GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$66.86 (29.29% Upside)
$66.86 (29.29% Upside)
Blogger Sentiment
Bullish
GRAL Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
91.51%
12-Months-Change
Fundamentals
Return on Equity
-16.42%
Trailing 12-Months
Asset Growth
-1.55%
Trailing 12-Months
Company Description
GRAIL Inc
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
GRAL Earnings Call
Q4 2026
0:00 / 0:00
GRAL Stock 12 Month Forecast
Average Price Target
$66.86
▲(29.29% Upside)
Technical Analysis
Ownership Overview
19.77% Insiders
13.42% Mutual Funds
2.67% Other Institutional Investors
50.39% Public Companies and
Individual Investors